Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...

Crenessity is expected to be available commercially in approximately 1 week through PANTHERx Rare, a specialty pharmacy. The Food and Drug Administration (FDA) has approved Crenessity TM (crinecerfont ...

Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated. Nonclassical congenital ...

The treatments for both classic and nonclassic congenital adrenal hyperplasia (CAH) include medication, surgery, and psychological support, or a combination of all three. Some people who have CAH, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Disease control and reduced glucocorticoid doses ...

The US Food and Drug Administration has approved crinecerfont (Crenessity) for use in combination with glucocorticoids in the treatment of adults and children aged 4 years or older with classic ...

CAH is a condition in which a gene that tells the body how to make an enzyme called 21-hydroxylase, which helps make cortisol and aldosterone, doesn't work properly. For you to have CAH, both of your ...

Orlando, Florida — New data add to the evidence supporting use of crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, in both adults and children.

Management of classic congenital adrenal hyperplasia (CAH), a rare genetic condition diagnosed at birth, requires a careful balance between androgen and cortisol. Most often caused by a genetic ...

Congenital adrenal hyperplasia (CAH) is a rare genetic condition present from birth. A person with CAH lacks one of the enzymes needed for their adrenal glands to work correctly. Sitting above the ...